# TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

> **NCT06961786** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **TILT Biotherapeutics Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** TILT-123
- **BIOLOGICAL:** TIL
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT06961786
- **Lead sponsor:** TILT Biotherapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-25
- **Primary completion:** 2026-11
- **Final completion:** 2027-04
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06961786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06961786, "TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06961786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*